Trial Profile
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Colon cancer; HER2 positive breast cancer; Male breast cancer; Meningeal carcinomatosis
- Focus Adverse reactions; Therapeutic Use
- 29 May 2019 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 13 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.